Flexion Therapeutics (FLXN) PT Set at $39.00 by Wells Fargo

Wells Fargo set a $39.00 price objective on Flexion Therapeutics (NASDAQ:FLXN) in a report issued on Tuesday morning. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.

Several other equities analysts have also issued reports on the stock. BidaskClub lowered shares of Flexion Therapeutics from a sell rating to a strong sell rating in a report on Saturday, January 20th. Berenberg Bank initiated coverage on shares of Flexion Therapeutics in a report on Thursday, February 1st. They issued a buy rating and a $42.00 price target on the stock. ValuEngine raised shares of Flexion Therapeutics from a sell rating to a hold rating in a report on Sunday, December 31st. Zacks Investment Research lowered shares of Flexion Therapeutics from a hold rating to a sell rating in a report on Tuesday, January 30th. Finally, BMO Capital Markets reaffirmed an outperform rating and issued a $36.00 price target (down from $37.00) on shares of Flexion Therapeutics in a report on Friday, March 9th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus price target of $99.00.

How to Become a New Pot Stock Millionaire

NASDAQ FLXN traded down $0.10 on Tuesday, hitting $23.52. The stock had a trading volume of 110,598 shares, compared to its average volume of 774,181. The company has a current ratio of 13.02, a quick ratio of 12.96 and a debt-to-equity ratio of 0.58. Flexion Therapeutics has a 52-week low of $16.51 and a 52-week high of $32.25. The firm has a market capitalization of $937.85, a P/E ratio of -5.65 and a beta of 0.83.

Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings results on Thursday, March 8th. The specialty pharmaceutical company reported ($1.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.11) by ($0.27). The business had revenue of $0.36 million for the quarter, compared to analyst estimates of $1.29 million. sell-side analysts predict that Flexion Therapeutics will post -4.89 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in FLXN. Wells Fargo & Company MN grew its holdings in shares of Flexion Therapeutics by 1,024.1% during the fourth quarter. Wells Fargo & Company MN now owns 1,706,942 shares of the specialty pharmaceutical company’s stock valued at $42,742,000 after buying an additional 1,555,093 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Flexion Therapeutics by 17.4% during the fourth quarter. BlackRock Inc. now owns 2,650,986 shares of the specialty pharmaceutical company’s stock valued at $66,381,000 after buying an additional 392,055 shares during the last quarter. Perceptive Advisors LLC purchased a new stake in shares of Flexion Therapeutics during the fourth quarter valued at $7,712,000. Ardsley Advisory Partners grew its holdings in shares of Flexion Therapeutics by 137.1% during the fourth quarter. Ardsley Advisory Partners now owns 415,000 shares of the specialty pharmaceutical company’s stock valued at $10,392,000 after buying an additional 240,000 shares during the last quarter. Finally, American Financial Group Inc. purchased a new stake in shares of Flexion Therapeutics during the fourth quarter valued at $5,280,000. 94.46% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Flexion Therapeutics (FLXN) PT Set at $39.00 by Wells Fargo” was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3335321/flexion-therapeutics-flxn-pt-set-at-39-00-by-wells-fargo.html.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Analysts Set Granite Construction  PT at $73.00
Analysts Set Granite Construction PT at $73.00
Salesforce.com  Receives Consensus Recommendation of “Buy” from Analysts
Salesforce.com Receives Consensus Recommendation of “Buy” from Analysts
Reliance Steel & Aluminum  and L.B. Foster  Critical Survey
Reliance Steel & Aluminum and L.B. Foster Critical Survey
Head to Head Survey: ZTE  and Absolute Software
Head to Head Survey: ZTE and Absolute Software
Dovu  Price Up 54.1% This Week
Dovu Price Up 54.1% This Week
Critical Survey: Dorian LPG  & Global Ship Lease
Critical Survey: Dorian LPG & Global Ship Lease


© 2006-2018 Ticker Report. Google+.